InvestorsHub Logo
Followers 131
Posts 11471
Boards Moderated 0
Alias Born 01/06/2010

Re: None

Monday, 10/10/2016 4:35:54 PM

Monday, October 10, 2016 4:35:54 PM

Post# of 1085
Mid to Late 2017 should be a pivotal time for RVX. Thanks to BearDownAZ....

"...The DSMB will conduct additional periodic reviews and will also perform a futility assessment once 125 adjudicated major adverse cardiac events (MACE) have been observed. Resverlogix, the clinical steering committee, and all investigators remain blinded to the actual safety and efficacy results." We've heard before that the futility assessment is projected to occur likely in mid 2017."